GH Research (NASDAQ:GHRS) Sees Unusually-High Trading Volume - Should You Buy?

GH Research PLC (NASDAQ:GHRS - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 304,799 shares changed hands during mid-day trading, an increase of 92% from the previous session's volume of 158,809 shares.The stock last traded at $9.85 and had previously closed at $9.39.

Analyst Ratings Changes

GHRS has been the subject of several research reports. Cantor Fitzgerald initiated coverage on GH Research in a research report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 target price for the company. Stifel Nicolaus lifted their target price on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Royal Bank of Canada initiated coverage on GH Research in a research report on Friday. They issued an "outperform" rating and a $31.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Finally, Canaccord Genuity Group decreased their target price on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, GH Research has an average rating of "Buy" and a consensus price target of $30.67.

GH Research Trading Down 0.5 %

The firm has a market cap of $546.29 million, a price-to-earnings ratio of -13.29 and a beta of 0.94. The stock has a 50-day moving average of $10.80 and a 200-day moving average of $9.17.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. As a group, research analysts expect that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of GH Research

Several hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. raised its stake in GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock valued at $44,734,000 after acquiring an additional 85,000 shares in the last quarter. Lynx1 Capital Management LP raised its stake in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Diadema Partners LP bought a new stake in GH Research during the 4th quarter valued at $711,000. Woodline Partners LP raised its stake in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after acquiring an additional 41,711 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock valued at $508,000 after acquiring an additional 3,092 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).